Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva

WASHINGTON, March 31, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today the completion of its acquisition of the Biopharma business from General Electric Company’s (NYSE: GE) Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher’s Life Sciences segment.

ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher’s globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life’s Potential. For more information, please visit www.danaher.com.

SOURCE Danaher Corporation

For further information: Matthew E. Gugino, Vice President, Investor Relations, Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860; MEDIA CONTACT: George Sard, Sard Verbinnen & Co, Telephone: (212) 687-8080, Email: gsard@sardverb.com